Abstract
Different studies highlight photo-receptors’ presence on the hair follicle that seems to be capable of eliciting hair growth. This study aims to demonstrate blue light’s effectiveness on hair growth in patients affected by androgenetic alopecia. Twenty patients enrolled at Magna Graecia University Unit of Dermatology, affected by androgenetic alopecia, were treated with a blue LED light device at 417 ± 10 nm, fluence of 120 J/cm2, and power intensity of 60 mW/cm2 ± 20%. The treatments were performed twice a week for ten consecutive weeks. Patients were evaluated before and 1 month after the end of therapy clinically using standardized global photographs and dermoscopically estimating hair density and hair shaft width. An increase in hair density and hair shaft width was recorded in 90% of patients after 10 weeks. Photographic improvement was noted in 80% of the patients. No serious adverse events have been reported. The only side effect consisted in a darkening of the hair, perhaps due to melanic stimulation due to blue light in 2 patients. Blue light therapy is a promising therapy for patients affected by androgenetic alopecia and other diseases characterized by hair loss. Further studies will be necessary to confirm the findings of this preliminary study.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
Androgenetic alopecia (AGA) is the leading cause of the progressive thinning of the scalp. Over 40% of Caucasian men develop hair loss by the age of 40, and, in the world, over 80% of the male population and 50% of the female population are affected by this condition [1]. The transformation of testosterone into dihydrotestosterone, a more active metabolic form also formed at hair follicles level thanks to the intervention of an enzyme called 5-alpha-reductase type 2, acts progressively shortening and thinning hair follicles until their disappearance [2].
Different treatments have been proposed for the treatment of AGA. Currently, two drugs are widely used for the treatment of this condition: minoxidil and finasteride. Unfortunately, the effects of these substances on hair growth are evident only after several months and require daily assumptions. Patients’ compliance decreases with long-term use of these drugs [3]. Platelet-rich plasma injections and hair transplants have also been proposed [4]. Some studies have shown that LLLT (low-level laser therapy) stimulated hair growth in males and females. The wavelengths experimented ranged mainly from orange (635–650 nm) to near-infrared (800–900 nm), but other studies are necessary to determine the most effective wavelength [5,6,7]. To our knowledge, blue light therapy (BLT) has never been proposed for AGA treatment.
This study aims to evaluate the use of BLT in AGA to assess hair growth.
Materials and methods
Twenty male patients aged between 22 and 60 (mean age 38.55 ± 11.68 years old) affected by moderate–severe AGA (with a Norwood-Hamilton score from 3 to 6 [8]) were recruited at the Unit of Dermatology of Magna Graecia University (Catanzaro, Italy). Inclusion criteria were the following: no treatment for AGA or use of anti-androgen drugs in the last 6 months, absence of any autoimmune or systemic condition, and lack of other dermatological conditions interesting the scalp. We treated the patients with BLT (wavelength 417 ± 10 nm, fluence 120 J/cm2, and power intensity 60 mW/cm2 ± 20%). The treatments were performed twice a week for ten consecutive weeks. Each session was characterized by overall exposure to the Blue light of 24 min. Each patient signed informed consent and photo release. The study was approved by the Local Ethical Committee (Comitato Etico Calabria Centro: reference number 37319). As the Norwood-Hamilton scale is non-linear (significant improvements not always correspond to an improvement in the scoring and vice-versa), the primary endpoint was digital photographic evaluation. Researchers took digital photographs before and 1 month after treatment (Nikon D5600, Nikon, Minato City, Tokyo, Japan). Two independent dermatologists ranked the photographic patient results as no improvement (response under 20% or further air loss), good improvement (response from 20 to 50%), and excellent improvement (response over 50%). In case of discrepancies between the physicians, a third dermatologist was called to solve them. Patients were also evaluated with a digital trichoscope to assess hair density and hair shaft width before and 1 month after treatment (Horus HS 1000 trichoscopy system, Adamo SRL, Trapani Italy). Hair shaft width and density were measured in the most advanced part of the hairline and then remeasured in the same spot. Researchers analyzed data for statistical significance with SPSS Statistics version 27.0 (IBM, Armonk, New York). Mean and standard deviations for all groups were calculated. Student’s t test for paired data was used to assess statistical significance. A p-value inferior to 0.05 was considered significant.
Results
The photographic evaluation showed a good improvement in 16 out of 20 patients (80%); 4 patients (20%) reported no change of the condition (Figs. 1, 2 and 3). Mean hair density measured before treatment was 106 ± 66 units/cm2; mean hair density measured after treatment was 117 ± 69 units/cm2. Mean hair density improvement was statistically significant (p = 0.001). The mean hair shaft width measured before treatment was 0.0295 ± 0.017 mm. The mean hair shaft width measured after treatment was 0.034 ± 0.017 mm. Mean hair shaft width improvement was statistically significant (p = 0.009). An increase in hair density and hair shaft width was recorded in 18 (90%) patients after 10 weeks. As expected, the patients that did not show any improvement at photographic evaluation tended to report worsening or stable hair density and hair shaft width (Table 1). Researchers noted no serious adverse events; the only side effect reported in 6 out of 20 patients (30%) was a slight darkening of hair.
Discussion
The results observed highlight a positive impact of BLT on hair density and hair shaft width, suggesting this therapeutic option as complementary or a possible alternative to the traditional therapies such as minoxidil or anti-androgens. The exact molecular mechanism underlying light-mediated hair regrowth remains mostly unknown, but the effects of BLT could be mediated by the photolytic generation of NO from nitrosated proteins. Treatment with blue light-emitting diode devices significantly prolonged the anagen phase in hair follicles ex vivo [9]. Recent discoveries opened an exciting field of research: the photoreceptors OPN2 (rhodopsin) and OPN3 (panopsin, encephalopsin) absorbing light in visible blue-green wavelength range are expressed in human skin, human epidermal keratinocytes, mesenchymal components, and in the distinct compartments of the anagen human follicles [7,8,9,10]. The expression of OPN2 and OPN3 was detected in the distinct compartments of skin and anagen hair follicle using real-time qualitative polymerase chain reaction, and immunofluorescence approaches a 453 nm BLT at low radiant exposure that exerts a positive effect on hair growth ex vivo, potentially via interaction with OPN3 [9]. OPN3 and the multimeric tyrosinase/tyrosinase-related protein complex induced after its activation appear as new potential targets for regulating melanogenesis. The melanin synthesis occurs in melanocytes inside melanosomes where melanogenic enzymes (tyrosinase and related proteins) are addressed with specific protein complexes. The melanosomes loaded with melanin are then transferred to keratinocytes [9]. BLT could interact with many enzymes and proteins like light-activated enzyme, cytochrome C oxidase [11], intracellular calcium, and light-gated ion channels [12] and NADPH oxidase, nitrosated proteins [13], and activate secondary messengers, like nitric oxide and other ROS, cAMP, ATP, and Ca2þ [14]. Cytochrome C oxidase plays a role of a light acceptor with absorption bands in red and near-infrared (NIR) range (650–980 nm) and an even higher extinction coefficient in a blue-green spectral range (400–500 nm) [15].
Researchers noted a darkening of the hair in 30% of patients. This side effect could perhaps be explained by the interaction of BLT with the OPN3 photoreceptor. OPN3, highly expressed in human epidermal melanocytes [16], is the critical sensor in melanocytes responsible for hyperpigmentation induced by the shorter wavelengths of visible light [17]. Its mechanism of action seems to generate an increase in melanin synthesis [18]. Regazzetti et al. recently reported that visible blue light stimulates opsin3-regulated calcium-dependent microphthalmia-associated transcription factor activation that increases pigment gene expression: it also causes the clustering of melanogenic enzymes [19]. OPN3 downregulation induces apoptosis of human epidermal melanocytes via mitochondrial pathway: it is a crucial signal responsible for cell survival through a calcium-dependent G protein-coupled signaling mitochondrial pathway [20].
Photobiomodulation has been clinically reported to have a positive impact on many dermatological conditions and hair growth [21, 22]. In particular, BLT has already been used to treat patients with rosacea [23], atopic dermatitis [24], and psoriasis, with variable results. Although photobiomodulation was already proposed for AGA treatment, this study is the first to use a 417 nm diode in the treatment of AGA, with good results.
Conclusions
Our clinical study’s preliminary result seems to confirm the results reported in vitro by other researchers, highlighting the therapeutic effects of BLT in AGA treatment. We provide the first in vivo evidence that BLT has a positive effect on hair growth. Limitations of this study include the small sample size and the lack of a control group. Combining this treatment with other topical and systemic treatments for androgenetic alopecia to enhance its effect is possible. Further studies are needed to clarify the mechanisms of action and to evaluate the clinical effects of BLT better; specifically, a randomized clinical trial on a large number of participants and with the use of videomicroscopy will be necessary to confirm our findings.
Data availability
Available after request due to privacy from corresponding author.
Code availability
Not applicable.
References
Dhurat R, Sharma A, Rudnicka L, Kroumpouzos G, Kassir M, Galadari H, Wollina U, Lotti T, Golubovic M, Binic I, Grabbe S, Goldust M (2020) 5-Alpha reductase inhibitors in androgenetic alopecia: shifting paradigms, current concepts, comparative efficacy, and safety. Dermatol Ther 33(3):e13379
Katzer T, Leite Junior A, Beck R, da Silva C (2019) Physiopathology and current treatments of androgenetic alopecia: going beyond androgens and anti-androgens. Dermatol Ther 32(5):e13059
Zhou Y, Chen C, Qu Q, Zhang C, Wang J, Fan Z, Miao Y, Hu Z (2020) The effectiveness of combination therapies for androgenetic alopecia: a systematic review and meta-analysis. Dermatol Ther 33(4):e13741
Keaney T (2015) Emerging therapies for androgenetic alopecia. J Drugs Dermatol 14(9):1036–1040
Avci P, Gupta GK, Clark J, Wikonkal N, Hamblin MR (2014) Low-level laser (light) therapy (LLLT) for treatment of hair loss. Lasers Surg Med 46(2):144–151. https://doi.org/10.1002/lsm.22170
Afifi L, Maranda EL, Zarei M, Delcanto GM, Falto-Aizpurua L, Kluijfhout WP, Jimenez JJ (2017) Low-level laser therapy as a treatment for androgenetic alopecia. Lasers Surg Med 49(1):27–39. https://doi.org/10.1002/lsm.22512
Lanzafame RJ, Blanche RR, Chiacchierini RP, Kazmirek ER, Sklar JA (2014) The growth of human scalp hair in females using visible red light laser and LED sources. Lasers Surg Med 46(8):601–607. https://doi.org/10.1002/lsm.22277
Guarrera M, Cardo P, Arrigo P, Rebora A (2009) Reliability of hamilton-norwood classification. Int J Trichol 1(2):120–122
Tsutsumi M, Ikeyama K, Denda S, Nakanishi J, Fuziwara S, Aoki H, Denda M (2009) Expressions of rod and cone photoreceptorlike proteins in human epidermis. Exp Dermatol 18(6):567–570
Buscone S, Mardaryev AN, Raafs B, Bikker JW, Sticht C, Gretz N, Farjo N, Uzunbajakava NE, Botchkareva NV (2017) A new path in defining light parameters for hair growth: discovery and modulation of photoreceptors in human hair follicle. Lasers Surg Med 49(7):705–718. https://doi.org/10.1002/lsm.22673
Serre C, Busuttil V, Botto J-M (2018) Intrinsic and extrinsic regulation of human skin melanogenesis and pigmentation. Int J Cosmet Sci 40(4):328–347. https://doi.org/10.1111/ics.12466
Karu TI (2014) Cellular and molecular mechanisms of photobiomodulation (low-power laser therapy). IEEE J Sel Top Quantum Electron 20(2):143–148
Wang Y, Huang YY, Wang Y, Lyu P, Hamblin MR (2016) Photobiomodulation (blue and green light) encourages osteoblasticdifferentiation of human adipose-derived stem cells: role of intracellular calcium and light-gated ion channels. Sci Rep 6:33719
Oplander C, Deck A, Volkmar CM et al (2013) mechanism and biological relevance of blue-light (420–453nm)-induced nonenzymatic nitric oxide generation from photolabile nitric oxide derivates in human skin in vitro and in vivo. Free Radic Biol Med 65:1363–1377
Mignon C, Botchkareva NV, Uzunbajakava NE, Tobin DJ (2016) Photobiomodulation devices for hair regrowth and wound healing: a therapy full of promise but a literature full of confusion. Exp Dermatol 25:745–749
Wicks NL, Chan JW, Najera JA, Ciriello JM, Oancea E (2011) UVA phototransduction drives early melanin synthesis in human melanocytes. Curr Biol 21(22):1906–1911
Ozdeslik RN, Olinski LE, Trieu MM, Oprian DD, Oancea E (2019) Human nonvisual opsin 3 regulates pigmentation of epidermal melanocytes through functional interaction with melanocortin 1 receptor. Proc Natl Acad Sci U S A 116(23):11508–11517. https://doi.org/10.1073/pnas.1902825116
Subba Rao Setty (2018) Opsin3-A link to visible light-induced skin pigmentation. J Invest Dermatol 138(1):13–15. https://doi.org/10.1016/j.jid.2017.09.025
Regazzetti C, Sormani L, Debayle D, Bernerd F, Tulic MK, De Donatis GM, Chignon-Sicard B, Rocchi S, Passeron T (2018) Melanocytes sense blue light and regulate pigmentation through Opsin-3. J Invest Dermatol. 138(1):171–178. https://doi.org/10.1016/j.jid.2017.07.833
Wang Yu, Lan Y, Hongguang Lu (2020) Opsin3 downregulation induces apoptosis of human epidermal melanocytes via mitochondrial pathway. Photochem Photobiol 96(1):83–93. https://doi.org/10.1111/php.13178
Lanzafame RJ, Blanche RR, Bodian AB, Chiacchierini RP, Fernandez-Obregon A, Kazmirek ER (2013) The growth of human scalp hair mediated by visible red light laser and LED sources in males. Laser Surg Med 45(8):487–495
Jimenez JJ, Wikramanayake TC, Bergfeld W, Hordinsky M, Hickman JG, Hamblin MR, Schachner LA (2014) Efficacy and safety of a low-level laser device in the treatment of male and female pattern hair loss: a multicenter, randomized, sham devicecontrolled, double-blind study. Am J Clin Dermatol 15(2):115–127
Sorbellini E, De Padova MP, Rinaldi F (2020) Coupled blue and red light-emitting diodes therapy efficacy in patients with rosacea: two case reports. J Med Case Rep 14(1):22. https://doi.org/10.1186/s13256-019-2339-6
Kromer C, Nühnen VP, Pfützner W et al (2019) Treatment of atopic dermatitis using a full-body blue light device (AD-Blue): protocol of a randomized controlled trial. JMIR Res Protoc 8(1):e11911. https://doi.org/10.2196/11911
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Ethics approval
The study was approved by the local ethical committee.
Consent to participate/publication
All patients gave their informed consent to participate to the study.
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Lodi, G., Sannino, M., Cannarozzo, G. et al. Blue light-emitting diodes in hair regrowth: the first prospective study. Lasers Med Sci 36, 1719–1723 (2021). https://doi.org/10.1007/s10103-021-03327-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10103-021-03327-9